Takeda Pharmaceutical Co (4502) Price & Analysis

Compare

6 Followers

4502 Stock Chart & Stats

¥4222.00

-¥15.00(-0.36%)

At close: Jan 08 4:00 PM EST

¥4222.00

-¥15.00(-0.36%)

Day’s Range― - ―

52-Week Range¥3,916.00 - ¥4,670.00

Previous CloseN/A

Volume3.70M

Average Volume (3M)4.32M

Market Cap

¥6.65T

Enterprise Value¥10.78T

Total Cash (Recent Filing)¥350.01B

Total Debt (Recent Filing)¥4.51T

Price to Earnings (P/E)194.4

Beta0.45

Next Earnings

Jan 29, 2026

EPS Estimate

46.32

Last Dividend Ex-Date

Sep 29, 2025

Dividend Yield4.63%

Share Statistics

EPS (TTM)-7.83

Shares Outstanding1,590,985,800

10 Day Avg. Volume4,124,760

30 Day Avg. Volume4,315,803

Financial Highlights & Ratios

PEG Ratio-2.51

Price to Book (P/B)1.00

Price to Sales (P/S)1.52

P/FCF Ratio9.15

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥5,150.72

Price Target Upside22.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)143.59

Revenue Forecast (FY)¥4.52T

Bulls Say, Bears Say

Bulls Say

Clinical TrialsFavorable Ph3 results for orexin receptor agonist oveporexton for NT1 presented.

Market PerformanceEntyvio continues to grow faster than the market many years into its launch, and neither biosimilar step edits nor branded competition from IL-23s seem to yet have made a major dent.

Safety And TolerabilityNo serious treatment-related adverse events and no hepatotoxicity were reported.

Bears Say

Government InitiativesMFN poses a threat not just because of its direct implications, but also because of the way in which prices are determined for 340b.

Pricing HeadwindsEntyvio faces potential pricing headwinds via two government initiatives: MFN and IRA.

Takeda Pharmaceutical Co News

Takeda presents interim data from Phase 1b study of mezagitamab

Takeda (TAK) announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab, an anti-CD38...

1d ago

TAK

Takeda completes seven-year Phase 3 TIDES trial of Qdenga

Takeda (TAK) announced the completion of the seven-year Phase 3 TIDES trial evaluating its dengue vaccine, Qdenga. These...

5d ago

TAK

Citizens JMP healthcare analysts hold an analyst/industry conference call

Healthcare Analysts discuss emerging therapies in chronic myeloid leukemia (CML), (relevant companies NVS, ENLV, TERN, TAK, BMY, PFE)...

16d ago

BMY

NVS

Innovent Biologics announces global strategic partnership with Takeda

Innovent Biologics (IVBXF) announced a strategic global collaboration with Takeda (TAK) to advance next-generation IO and ADC cancer...

18d ago

TAK

Keros Therapeutics announces share repurchase program

Keros Therapeutics (KROS) announced that, as part of its previously announced $375M capital return program, it has entered...

24d ago

TAK

KROS

Takeda Pharmaceutical Reports Decline in Revenue and Profit

Takeda Pharmaceutical Co ( ($TKPHF) ) has released its Q2 earnings. Here is a breakdown of the information...

9d ago

Takeda Revises Financial Forecast for FY2025 Amid Strategic Shifts

Takeda Pharmaceutical Co ( ($JP:4502) ) has provided an update. Takeda Pharmaceutical Co has revised its financial forecast...

10d ago

Takeda Pharmaceutical Reports Decline in Six-Month Financial Results, Adjusts Fiscal Year Forecasts

An update from Takeda Pharmaceutical Co ( ($JP:4502) ) is now available. Takeda Pharmaceutical reported a decline in...

10d ago

Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role

Welcome to the latest edition of “Sector Spotlight,” where The Fly looks at a new industry every week...

1M ago

Nike reports Q1 beat, U.S. takes 5% stake in Lithium Americas: Morning Buzz

The major averages were mixed near noon as traders grapple with the U.S. government shutdown. It’s unclear how...

1M ago

AES

Takeda to discontinue cell therapy efforts

Takeda (TAK) announced that as part of a strategic portfolio prioritization process, the company has made the decision...

1M ago

TAK

Takeda Discontinues Cell Therapy Efforts to Refocus Investments

An update from Takeda Pharmaceutical Co ( ($JP:4502) ) is now available. Takeda Pharmaceutical Co has decided to...

1M ago

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: CEA Industries Inc (BNC)...

1M ago

BNC

CEP

Bristol Myers, Takeda, Astex to contribute data for AI tool, Reuters says

Bristol Myers Squibb (BMY), Takeda Pharmaceuticals (TAK), and Astex Pharmaceuticals are joining a consortium that include AbbVie (ABBV)...

1M ago

BMY

JNJ

4502 FAQ

What was Takeda Pharmaceutical Co’s price range in the past 12 months?

Takeda Pharmaceutical Co lowest stock price was ¥3916.00 and its highest was ¥4670.00 in the past 12 months.

What is Takeda Pharmaceutical Co’s market cap?

Takeda Pharmaceutical Co’s market cap is ¥6.65T.

When is Takeda Pharmaceutical Co’s upcoming earnings report date?

Takeda Pharmaceutical Co’s upcoming earnings report date is Jan 29, 2026 which is in 82 days.

How were Takeda Pharmaceutical Co’s earnings last quarter?

Takeda Pharmaceutical Co released its earnings results on Oct 30, 2025. The company reported -¥7.83 earnings per share for the quarter, missing the consensus estimate of ¥20.735 by -¥28.565.

Is Takeda Pharmaceutical Co overvalued?

According to Wall Street analysts Takeda Pharmaceutical Co’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Takeda Pharmaceutical Co pay dividends?

Takeda Pharmaceutical Co pays a Semiannually dividend of ¥100 which represents an annual dividend yield of 4.63%. See more information on Takeda Pharmaceutical Co dividends here

What is Takeda Pharmaceutical Co’s EPS estimate?

Takeda Pharmaceutical Co’s EPS estimate is 46.32.

How many shares outstanding does Takeda Pharmaceutical Co have?

Takeda Pharmaceutical Co has 1,590,985,800 shares outstanding.

What happened to Takeda Pharmaceutical Co’s price movement after its last earnings report?

Takeda Pharmaceutical Co reported an EPS of -¥7.83 in its last earnings report, missing expectations of ¥20.735. Following the earnings report the stock price went up 0.543%.

Which hedge fund is a major shareholder of Takeda Pharmaceutical Co?

Currently, no hedge funds are holding shares in JP:4502

Company Description

Takeda Pharmaceutical Co

Takeda Pharmaceutical Company Limited, headquartered in Tokyo, Japan, is a global biopharmaceutical leader focused on the research, development, manufacturing, and marketing of innovative medicines. The company operates in several therapeutic areas, including oncology, gastroenterology, neuroscience, rare diseases, and vaccines. Takeda's core products include treatments for various cancers, gastrointestinal disorders, and rare diseases, alongside a growing portfolio of vaccines and biologics.

Takeda Pharmaceutical Co (4502) Earnings & Revenues

Historic Earnings Reports

4502 Company Deck

4502 Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflected a mixed financial performance with strong cash flow and pipeline advancements but was overshadowed by significant challenges such as the VYVANSE generic impact, ENTYVIO's slower growth, and foreign exchange headwinds. The partnership with Innovent Biologics provides a positive outlook for the oncology pipeline, but current financial pressures remain a concern.View all JP:4502 earnings summaries

4502 Stock 12 Month Forecast

Average Price Target

¥5,150.72

▲(22.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3938":"¥3,938","4769":"¥4,769","5600":"¥5,600","4353.5":"¥4,353.5","5184.5":"¥5,184.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5599.8154414433,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥5.60K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5150.7228545437,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥5.15K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4500.1537988638,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥4.50K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3938,4353.5,4769,5184.5,5600],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4153,4264.293495495638,4375.586990991277,4486.880486486915,4598.173981982554,4709.467477478192,4820.760972973831,4932.05446846947,5043.347963965108,5154.641459460747,5265.934954956385,5377.228450452023,5488.521945947662,{"y":5599.8154414433,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4153,4229.747911887977,4306.495823775954,4383.243735663931,4459.991647551908,4536.739559439885,4613.487471327861,4690.235383215839,4766.983295103815,4843.7312069917925,4920.479118879769,4997.227030767746,5073.974942655723,{"y":5150.7228545437,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4153,4179.704138374139,4206.408276748277,4233.112415122416,4259.816553496554,4286.520691870693,4313.224830244831,4339.9289686189695,4366.6331069931075,4393.337245367246,4420.041383741384,4446.745522115523,4473.449660489661,{"y":4500.1537988638,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3967.512,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3939.774,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3999.076,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4025.857,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4145.419,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4407.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4273.487,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4179.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4294.991,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4121.979,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4368.301,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4260,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4153,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >